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Treatment of acute allograft rejection with high doses of corticos-
teroids. Sixty-four rejection crises in 55 kidney transplant patients
were treated with high doses of corticosteroids, either 1) pred-
nisone, administered orally in doses ranging between 150 and 600
mg/day; 2) methylprednisolone, administered iv. in doses ofO.5 to
1 g/day (total dose: 2 to 8 g); or3) methylprednisone administered
i.v. in the same dosage in combination with heparin 5000 U/day.
Acute rejection was reversed successfully in 60% of the crises
without any apparent difference between the three treatment
groups. Nineteen patients died from steroid-related complications.
A total methylprednisolone dosage exceeding 3 to 5 g apparently
was not accompanied by a sufficiently improved therapeutic re-
sponse to warrant the high risk of such treatment.
Traitement du rejet aigu par des doses élevées de prednisone.
Soixante quatre crises de rejet chez 55 malades ayant subi une
transplantation rénale ont été traitées par des doses élevées de
corticostéroides, soit 1) de Ia prednisone par voie orale a des doses
de 150 a 600mg par jour, soit2) de Ia methylprednisone par voie
intraveineuse a des doses de 0,5 a I g parjour (dose totale: 2 a 8 g),
soit 3) de Ia methylprednisone aux mêmes doses en association
avec 500 unites d'héparine par jour. Le rejet aigu a été supprimé
dans 60 pour cent des crises sans differences apparentes entre les
trois groupes de traitements. Dix-neuf malades sont morts de
complications imputables au traitement par les stéroIdes. Une dose
totale de methyiprednisone supérieure a 3-5 g ne paraIt pas en-
traIner une amelioration suffisante de Ia réponse au traitement
pour justifier I'importance du risque thérapeutique.
Treatment of acute allograft rejection is one of
the major problems in renal transplantation. Vari-
ous regimens have been tried: corticosteroids in high
doses, actinonlycin C, anticoagulants, antilymphocyte
globulin and graft irradiation [1-7].
Remission of the rejection crisis has been reported
in up to 90% of patients with renal allografts follow-
ing the administration of steroids in high doses [1, 2,
7]. The present paper offers a review of our own
results from treating patients in severe acute rejection
crises with high doses of steroids administered orally,
i.v. or i.v. together with anticoagulants.
Methods
During the two first months after transplantation,
64 severe acute rejection crises were observed in 55
patients from a consecutive experience with 229 cada-
veric kidney transplantations. This number of acute
rejections represents a minimal figure as it comprises
only those crises where the absolute increase in the
serum creatinine concentration exceeded 0.5 mg/l00
ml within two to three days during the rejection. The
material thus does not include eight episodes in which
this criterion was not fulfilled, episodes without a
change in kidney function where high doses of ster-
oids were administered because rejection was sus-
pected but not later confirmed, more chronic types of
rejection and one case of hyperacute rejection. Nor
does it include eight episodes of rejection which oc-
curred in patients with parallel evidence of acute
nonimmunologic complications (infections, vascular
complications, etc.) as the presence of these com-
plications made it difficult to evaluate the outcome.
The diagnosis of rejection was made on the basis of
clinical and laboratory data showing a reduction in
the renal function that was not otherwise explainable.
It was confirmed retrospectively by the effect of ster-
oid treatment or by microscopy following removal of
the graft. Furthermore, '311-renography and i.v. uro-
graphy were performed in all patients at an early
stage of the crisis in order to rule out that reduced
renal function was caused by nonimmunologic vascu-
lar disturbances, obstructive uropathy, leakage of
urine into the tissue, etc.
The present material thus derives from 55 grafts in
29 men and 26 women aged from 4 to 61 yr (mean,
42.5 yr). Of the 64 crises in these 55 allografts, 55
were the first while 9 were the second crisis occurring
in the graft. The patients were grouped according to
the treatment as described in the following. The treat-
ment groups (Table 1) did not differ greatly with
respect to age or sex. HL-A tissue typing was per-
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Table 1. Clinical data in three groups of recipients of cadaveric kidney transplants treated for allograft rejections with high doses of steroids
Group No.
Mean age
of patients
yr
Reject
First
ions, N
Second
Patients with
H-LA-anti-
bodies, N
Match grade, N
A/A-C, C/C-D,
D/D-E, E
Maintenance doses before
rejection, mean (± SEM)
Serum creatinine
before rejection,
mean (± SEM)
mg/IOOmlPrednisone, mg Imuran, mg
Ia (55) 12 4 2 1/6/4/1 82 + 13 95 6 1.9 2.3
11b (Il) 29 4 4 3/12/13/1 89±8 96±7 1.6 0.9
14 1 4 3/6/3/2 103 12 104 15 1.5 1.8
aGroup I: prednisone orally.
bGroup 11: methylprednisolone (Solu-Medrol) iv.
eGroup Ill: methylprednisolone + heparin iv.
formed before transplantation and showed full iden-
tity between the donor and recipient (A-match) in
seven cases. In 19 cases, one of the donor antigens
was not present in the recipient (C-match), in 12 cases
tissue typing showed two nonidentities (D-match)
and in 4 cases three nonidentities (E-match). Due to
an absence of information about the donor anti-
gens, five transplantations were characterized as A-C
matches and eight as C-D matches. The three groups
(Table I) did not differ greatly with respect to match-
grades.
Before transplantation it was ensured that the re-
cipient did not have circulating antibodies against the
donor HL-A antigens. Antibodies against other HL-
A antigens were present in ten of the recipients.
The endogenous creatinine clearance ranged be-
tween 15 and 65 mI/mm before rejection; the lowest
values were observed in kidneys that had not fully
recovered from posttransplantation acute renal fail-
ure. Overall, the creatinine clearance averaged 38,4
ml/min and the average prerejection plasma creati-
nine concentration equalled 1.6 mg/100 ml.
Initially all the patients received a basic immuno-
suppressive treatment with prednisone and azathio-
prine. Prednisone was first prescribed in doses from
80 to 150 mg/day for the first three weeks after
transplantation. The dose was then gradually reduced
to 30 mg/day over a period of two to three weeks
after transplantation. Azathioprine was given in
doses of 100 to 200 mg/day. The peripheral leuco-
cyte count was evaluated daily with the view of keep-
ing it below 4,000/mm3. The average maintenance
doses of prednisone and azathioprine in the three
treatment groups prior to rejection are shown in
Table 1.
The acute rejection episodes were divided into
three separate groups according to the treatment regi-
men:
Sixteen crises (group 1, Table 1) were treated for
three days with orally administered prednisone in
doses from 150 mg to 600 mg/day. The dose was then
gradually reduced to 30 mg/day over a period of one
to three weeks.
Forty-eight crises (groups II and III, Table I)
were treated for three to eight days with meth-
ylprednisolone sodium succinate (Solu-Medrol) i.v.
in total doses ranging between 2 and 8 g. Group
II received i.v. administered methyiprednisolone
alone. In addition to high-dose i.v. administered
methylprednisolone, 14 of the patients (group III
Table 1) also received heparin, 5000 U/day for about
one week. The initial i.v. administered dose of
methylprednisolone was 1 g; in groups II and III
subsequent doses ranged between 0.5 and 1 g/day
until the crisis was under control or such conditions
occurred that made it unwise to continue the treat-
ment.
After the methylprednisolone therapy, prednisone
was again given orally in the same dose as before the
crisis. The dosage was gradually reduced to about 30
mg/day. En nine cases, however, prednisone was
given in excessive doses (300 to 600 mg/day for three
days).
Therapy was considered to have been successful if
the endogenous creatinine clearance returned to the
same value as before the crisis.
Results
Table 2 shows the therapeutic results in the three
treatment groups. Overall successful results were
obtained in 38 (59%) of all crises. There was no
apparent difference in response to treatment among
the three groups. Complete reversal of the impaired
renal function was not obtained in 26 (41%) of the
crises, 19 of which represented the first crisis. Eleven
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Table 2. Results of treatment with high doses of steroids in 64 acute allograft rejections
Kind of treatment
High doses of
prednisone
Methyiprednisolone
sodium succinate
l.v.
Methylprednisolone
sodium succinate
iv. + heparin
High doses
of steroids
oral or i.v.
Evolution
Good 10(63%) 20(60%) 8(53%) 38(59%)
Bad 6(37%) 13(40%) 7(47%) 26(41%)
Crises, N 16 33 15 64
The criterion for good evaluation was complete restoration of the creatinine clearance to prerejection values.
of these 19 grafts had to be removed surgically
shortly after onset of the acute rejection, 6 of these 11
after a second crisis. Another 2 of the 19 allografts
ceased to function within one year. Four patients
died from complications in the presence of some de-
gree of preserved function of the allograft. After one
year, only 2 out of the 19 grafts had a function
sufficient to sustain life of the recipient. In one of
them more than one crisis had occurred.
In 38 of the 64 rejection crises, which include both
the first and the second crises in two recipients, the
creatinine clearance returned to the same level as that
observed before the crisis. However, 10 of these 36
grafts had to be removed later because of chronic
rejection, and another one ceased to function after a
new episode of acute rejection. Ten patients, whose
grafts were functioning, died within six months after
transplantation. One year after the crisis, only 15 of
36 grafts exhibited good function.
As compared to the first crisis of a graft, the second
was reversed less often. Successful results were ob-
tained in only 22% of these cases.
The result of the rejection treatment seemed to be
independent of the age and sex of the patient, the
elapsed time between transplantation and crisis
(within the said two months) and the occurence of
preformed HL-A antibodies. The results were neither
dependent on HL-A types nor match grades. Four of
the seven A-matches responded well initially, but
only two were functioning after one year.
Table 3 shows the patient survival for the 24
patients with rejection episodes. Twenty patients
died; in 17 of them the fatal complication occurred
within 14 days after treatment of the rejection. In 14
of them, the graft was still functioning up to death.
In association with the augmentation of immuno-
suppression, the following complications occurred:
severe psychosis (one patient), mild dyspepsia
(four patients), diabetes mellitus (two patients),
pneumonia (three patients), epididymitis (one
patient) and perforation of the colon (one patient
besides the one stated in Table 2). One year after
transplantation, 17 patients (27%) were alive with
functioning grafts. In these 17 patients, the creatinine
clearance averaged 44.1 ml/min (range, 13 to 65
mi/mm). Before the crises the average was 37.4
mI/mm. One-year graft survival in our entire experi-
ence with 229 cadaveric kidney transplantations has
averaged 44%.
Table 4 shows the relation between dose and
outcome of the treatment with methyiprednisolone.
Even in the patients receiving total doses as high as 5
to 8 g, the reversal of rejection was observed in only
about 60%—and only one of these grafts was func-
tioning one year after transplantation. In nine of
the crises, treatment was continued by oral ad-
ministration of prednisone in doses of 300 to 600
mg/day for three days. Apparently, this did not im-
prove the results either, as only six of these nine
(66%) responded well.
Discussion
During the last several years, the oral or i.v. admin-
istration of steroids in high doses has provided one of
the principal regimens for the management of acute
allograft rejection [1, 2, 6, 8]. Antilymphocyte glob-
Table 3. Recipient one-year survival and causes of death in 55
recipients of a cadaveric allograft when acute rejection was
treated with high doses of steroids
N
Alive, 31(56%)
Dialysis or retransplanted
With kidney function
Dead, 24 (44%)
Complications connected with
rejection episodes
Colon perforation
Gastrointestinal hemorrhage
Infections
Hemorrhagia cerebri
Complications occurring
later
Pancreatitis
Hpatitis
Infections
Hemorrhagia cerebri
Uremia
14
17
4
Ii
2
Total 55
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Successful Failure
Table 4. Relationship between the dose of methylprednisolone
and the results of treatment in 48 cadaveric allograft rejections
ol functioning after
methylprednisone one year
5(26%)
4(21%)
1(10%)
<3g 12(63%) 7(37%)
3—5 g 10(53%) 9(47%)
5—8 g 6(60%) 4(40%)
ulin, anticoagulants and actinomycin C have also been
used often in combination with high-dose steroid
therapy. Moreover, there has been a tendency toward
increasing the usage of high doses of steroids; meth-
ylprednisolone sodium succinate has been employed
especially often in high doses.
Theoretically, this drug offers several advantages:
rapid lympholytic effect, rapid metabolism, inhibi-
tion of lymphocyte transformation for about 72 hr
and no inhibition of the phagocytic function of leu-
cocytes [9, 10].
Bell et al [1], Feduska et al [2] and Woods et al [7]
reported about 90% reversal of acute rejection with
hardly any complications, even when very high doses
were employed (30 mg/kg/24 hr).
The present experience cannot confirm this high
degree of therapeutic success. Good results were ob-
tained in about 60% of all the rejection crises irrespec-
tive of regimen, and a great number of complications
were seen. Because allograft rejection is still not com-
pletely understood, and each rejection crisis involves
many uncertain aspects, the decision in each situa-
tion—whether to continue the treatment or to stop it
and let the patient return to hemodialysis—is a diffi-
cult one. Consequently, evaluation of the results of
such regimens is also difficult. The eventual outcome
is probably influenced by many unknown factors.
However, in the present ten cases where it was
necessary to administer more than 5 g of methyl-
prednisolone, only one graft was functioning af-
ter one year. Our results, therefore, do not appear
to warrant the usage of an antirejection treatment
which employs more than 3 g of methylprednisolone.
This is in accordance with the results of Siegel et al
[11].
The combination of steroids and small doses of
heparin did not improve our results. This is not quite
in accordance with other reports [3, 12, 13]. It is
possible that the present dose of heparin was too
small. Higher doses, however, may cause severe com-
plications in patients with hypertension or peptic ul-
cer disease.
Reprint requests to Dr. Jtlrgen Ladefoged, Rigshospitalet, Dept.
F, Blegdamsvej 9, Copenhagen, Denmark, DK 2100.
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